The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.
Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
Klick Health published “Cookies Crumble as Privacy Rises,” an industry POV on upcoming changes to the ways marketers will be able to target, track, and engage with consumers online.
This is the Age of Big Data – and also the Age of Data Vulnerability. How we as a society square these two realities will be important to all of us as citizens, consumers, and health communications professionals.
Healthcare consumers may love the idea of virtual care, but so far few are actually taking advantage of it. That’s the core message coming out of a recent Vivify Health survey, which showed 83 percent of consumers are interested in receiving virtual care, but only 17 percent have access to it.
Most U.S. consumers are very interested in receiving regular messages from their health plans – if those messages are highly relevant to them and can help them stay healthier and/or save money. That’s the conclusion drawn from a new online Pollfish survey of 400 consumers conducted on behalf of RxEOB who are members of commercial and government-sponsored health plans.
Norm Phillips, EVP and Chief Marketing Officer with BioPharm Communications, explains the challenges and opportunities for pharma and describes advantages they have compared to those in the consumer marketing world, such as identifiable influencers, customer-level data and access/reimbursement insights.
The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found.
Nestle entered exclusive talks to sell the company’s skin health business to a consortium led by EQT Partners for 10.2 billion Swiss francs ($10.1 billion), as the food group shifts its portfolio in response to changing consumer demands.
U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs and vowed to allow U.S. states to buy medicines from other countries if they cost less.
The Trump administration will require drugmakers to disclose the list price of prescription drugs in DTC TV advertisements, part of the government’s efforts to lower costs for U.S. consumers.